A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

计划入组 129 人 · 首次发布于 2013 年 6 月 20 日

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

计划入组 24 人 · 首次发布于 2024 年 8 月 16 日

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

首次发布于 2021 年 4 月 8 日

anti-CD22 degrader-antibody conjugates (non-Hodgkin lymphoma/NSCLC)

Bendamustine(Belrapzo, Bendeka, Treanda, Vivimusta)

C₁₆H₂₁Cl₂N₃O₂ · Rx

anti-CD19 CAR T-cell therapy (B-cell non-Hodgkin lymphoma)

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

ASSOCIATION INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)

Switzerland

The Cooper Health System, A New Jersey Non-Profit Corporation

United States

CAR-T Cell Therapy Shows Promise for Transformed Indolent Non-Hodgkin Lymphoma

Real-World Study Validates Rituximab-Lenalidomide Efficacy in Indolent Non-Hodgkin Lymphoma Treatment

Enterome's EO2463 Shows Promising CD8 T-Cell Expansion in Phase 2 Indolent Non-Hodgkin Lymphoma Trial